EOLS vs AVAH

For growth investors, Aveanna Healthcare Holdings Inc.

(AVAH) is the stronger pick with 20. 2% revenue growth year-over-year, versus 11. 6% for Evolus, Inc. (EOLS). Aveanna Healthcare Holdings Inc. (AVAH) offers the better valuation at 6. 6x trailing P/E (12. 0x forward), making it the more compelling value choice. Analysts rate Evolus, Inc. (EOLS) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Evolus, Inc.

(EOLS) delivered a total return of -30. 1%, compared to -39. 8% for Aveanna Healthcare Holdings Inc. (AVAH). Over 10 years, the gap is even starker: AVAH returned -42. 2% versus EOLS's -44. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Evolus, Inc.

(EOLS) is the lower-risk stock at 1. 27β versus Aveanna Healthcare Holdings Inc. 's 1. 40β — meaning AVAH is approximately 10% more volatile than EOLS relative to the S&P 500.

By revenue growth (latest reported year), Aveanna Healthcare Holdings Inc.

(AVAH) is pulling ahead at 20. 2% versus 11. 6% for Evolus, Inc. (EOLS). On earnings-per-share growth, the picture is similar: Aveanna Healthcare Holdings Inc. grew EPS 1952% year-over-year, compared to 1. 2% for Evolus, Inc.. Over a 3-year CAGR, EOLS leads at 26. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Aveanna Healthcare Holdings Inc.

(AVAH) is the more profitable company, earning 9. 2% net margin versus -17. 4% for Evolus, Inc. — meaning it keeps 9. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AVAH leads at 10. 9% versus -12. 7% for EOLS. At the gross margin level — before operating expenses — EOLS leads at 64. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for EOLS: 134.

7% to $15. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Evolus, Inc.

(EOLS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 27)). Both have compounded well over 10 years (EOLS: -44. 4%, AVAH: -42. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: EOLS is a small-cap quality compounder stock; AVAH is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.